Company Profile

Achieve Life Sciences Inc
Profile last edited on: 12/2/2023      CAGE: 8GZH3      UEI: JJKEN12FWSJ3

Business Identifier: Enabling effective smoking cessation
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

22722 29th Drive Se Suite 100
Bothell, WA 98021
   (425) 686-1500
Location: Multiple
Congr. District: 01
County: King

Public Profile

Achieve Life Sciences is a specialty pharmaceutical company structured around addressing the global smoking health and nicotine addiction epidemic through development and commercialization of cytisinicline. Cytisinicline (also known as cytisine) is a plant-based alkaloid with a high binding affinity to the ?4?2 nicotine receptor. Over the past 20 years, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction. Achieve’s focus is to address the global smoking health epidemic by making cytisinicline widely available.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $2,817,896
Project Title: Benefit and Safety of Cytisinicline (cytisine) for Cessation of Nicotine E-cigarette Use

Key People / Management

  John Bencich -- Chief Executive Officer

  Cindy Jacobs -- President and Chief Medical Officer

  Anthony Clarke -- Chief Scientific Officer

  Richard Stewart -- Executive Chairman of the Board of Directors

  Jaime Xinos -- Executive VP Commercial

Company News

There are no news available.